+340.4%
RF vs GSK
+81.4%
+259.0%
-60.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.1% | -1.9% | +1.9% | +0.6% |
| 7D | +1.3% | -1.8% | +3.1% | +1.9% |
| 30D | -3.6% | -2.2% | -1.4% | -3.1% |
| 3M | +8.1% | -1.8% | +9.9% | +8.4% |
| 6M | +11.5% | -10.6% | +22.1% | +15.3% |
| YTD | +15.6% | +4.4% | +11.1% | +13.0% |
| 1Y | +15.7% | +30.4% | -14.7% | +4.0% |
| 3Y | +86.9% | +60.1% | +26.8% | +49.0% |
| 5Y | +89.8% | +46.8% | +43.0% | +54.4% |
| All | +340.4% | +81.4% | +259.0% | +232.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling